Nasdaq

Abbott's XIENCE Stent Receives FDA Approval for Shortest Blood Thinner Course for High Bleeding Risk Patients

- XIENCE stents have 10+ years of clinical data across 120 clinical trials, more than 125,000 patients and 15 million stent¹ implants ABBOTT PARK, Ill., June 30, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ...
Medscape

FDA OKs 1-Month Dual Antiplatelet Therapy for Abbott's Xience Stents

The US Food and Drug Administration (FDA) has approved 1-month — as short as 28 days — dual antiplatelet therapy (DAPT) labeling for Xience stents in patients at high risk for bleeding, Abbott ...
Pharmabiz

Abbott introduces more flexible, easier to guide through the heart’s arteries drug eluting stent XIENCE Skypoint in India

Abbott, the global healthcare company, has launched XIENCE Skypoint in India. This is the company said is the most advanced generation stent within the globally trusted XIENCE family of everolimus ...
Insider Monkey

Abbott Laboratories (ABT) Unveils XIENCE Skypoint to Advance Cardiovascular Treatment in India

Abbott Laboratories (NYSE:ABT) is one of Goldman Sachs top healthcare stocks. On March 10, Abbott Laboratories (NYSE:ABT) confirmed the launch of its most advanced generation stent, XIENCE Skypoint, ...
MD&M East

Abbott Boosts DES Offerings with New Approvals

Abbott Laboratories is taking one huge step forward with its drug-eluting stent offerings. The Abbott Park, IL-based company said it has won CE mark approval for dual anti-platelet therapy for as ...
FiercePharma

Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated

-- Two-Year Results from Independent 'All-Comers' Study of 1,800 Real-World Patients Compared XIENCE V to the Newer-Generation TAXUS® Liberte® For the endpoint of major adverse cardiac events (MACE) ...
Nasdaq

Abbott's (ABT) DAPT for High Bleeding Risk Gets FDA Approval

Abbott Laboratories ABT recently announced the receipt of FDA approval for its XIENCE family of stents for one-month (as short as 28 days) DAPT labeling for high bleeding risk (HBR) patients in the ...
TCTMD

Abbott Receives U.S. FDA Approval for Next-Generation XIENCE PRIME™ Drug Eluting Stent

Designed for Enhanced Deliverability and Flexibility to Treat Patients with Complex Coronary Artery Disease Built Upon the Proven Clinical Outcomes of Abbott's Cobalt Chromium Stent Technology, With a ...
FierceBiotech

Abbott racks up 2 more U.S., EU approvals for Xience family of drug-eluting stents

They say if it ain’t broke, don’t fix it, but Abbott just can’t seem to resist making regular additions to its longstanding line of Xience stents. The product family received its first regulatory ...
FiercePharma

Abbott's XIENCE V® Shows Outstanding Two-Year Clinical Results Versus TAXUS® in Key Safety and Efficacy Measures in SPIRIT IV Tr

-- XIENCE V Shows Clinically Significant 30 Percent Risk Reduction Through Two Years in Composite Endpoint of Target Lesion Failure Compared to TAXUS ABBOTT PARK, Ill ...
TCTMD

Abbott Receives U.S. FDA Approval for XIENCE nano™ to Treat Coronary Artery Disease in Small Vessels

Abbott Now Offers a 2.25 mm Version of the Market-Leading XIENCE V® Drug Eluting Stent, Which Has Been Studied in More Than 30,000 Patients Worldwide Abbott Park, Illinois — Abbott today announced it ...